Recent study demonstrates potential pharmacokinetic advantages of using lysine butyrate over sodium butyrate or tributyrin

Photo © AdobeStock.com/BillionPhotos.com

A recent pharmacokinetic study¹ comparing three butyrate ingredients found that lysine butyrate (marketed as BIOMEnd by NutraShure Distribution LLC) and sodium butyrate had significantly higher peak plasma concentrations (Cmax) and faster times to maximum circulation (Tmax), compared to tributyrin. In the randomized, three-arm, cross-over clinical study, ten men between the ages of 25 and 45 ingested one of the three butyrate products, and had blood samples collected and assessed over a 3.5 hour post-ingestion period.

According to a press release from NutraShure, lysine butyrate had 500% greater Cmax than tributryn and 180% greater Cmax than sodium butyrate. “This study is the first comparative study of three commercially available forms of butyrate,” said Brandon Sojka, CEO at NutraShure, in the press release. “The exceptional pharmacokinetic advantage of BIOMEnd coupled with our new substantiated GLP-1 claims and superior delivery form allows us to provide a truly innovative solution for supporting gut health, weight management, and overall well-being.”

Reference

1. Le Monica, M.; Kirby, T.; Hartshorn, S.; Gustat, A.; Grdic, J.; Sandrock. A Pharmacokinetic Comparison of Three Butyrate Products. Journal of Exercise and Nutrition. 2025, 8 (10). DOI: 10.53520/jen2025.103189